NASDAQ · SERVICES-MEDICAL LABORATORIES · MID CAP
Castle Biosciences, Inc. CSTL
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$344.2M
▲ 3.7% vs FY2024
EPS · FY25
$-0.83
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-5.2%
Net margin · FY25
-7.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 344.2M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 7 cents on every revenue dollar this year.
Per share
USD -0.83
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-5.2%
Return on equity, FY2025
ROE
Operating margin-12.4%
Net margin-7.0%
Return on assets-4.4%
Each USD of equity lost 5 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+40.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+35.9%
+40.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+19.6%
Change, 10 years—
The share count grew 20% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 578.6M
total assets, end of FY2025
Total assetsUSD 578.6M
EquityUSD 470.9M
CashUSD 116.7M
Gross debtUSD 10.1M
Net debtUSD -106.7M
Current ratio5.26×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.3
0.3
0.2
0.1
0.1
0.1
0.1
0.0
Operating income $B
−0.0
0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
EBITDA $B
−0.0
0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
Income tax $B
−0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
0.0
−0.1
−0.1
−0.0
−0.0
0.0
−0.0
EPS, diluted $
−0.83
0.62
−2.14
−2.58
−1.24
−0.54
−0.21
−5.33
Dividend / sh $
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Payout %
·
·
·
·
·
·
·
·
ROE %
−5.2
4.3
−14.5
−16.6
−7.6
−4.1
37.0
·
Shares out B
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed